Use of NK-1 receptor antagonists in pruritus
View Patent ↗The invention relates to methods for treating pruritus with an NK-1 receptor antagonist. The invention further relates to pharmaceutical compositions comprising NK-1 receptor antagonist.
1. A method of treating chronic pruritus, said method comprising orally administering 3-[(3aR,4R,5S,7aS)-5-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-4-(4-fluorophenyl)-1,3,3a,4,5,6,7,7a-octahydroisoindol-2-yl]cyclopent-2-en-1-one or a pharmaceutically acceptable salt or solvate thereof to a patient in need of such treatment according to a schedule, said schedule comprising:
a) first administering at least one loading dose; and
b) second administering at least one therapeutically effect maintenance dose;
said maintenance dose is administered chronically and comprises a dosage from about 0.1 mg to about 7.5 mg.
2. The method according to claim 1 , wherein the loading dose is five times, four times, three times, or two times the maintenance dose.
3. The method according to claim 2 , wherein the loading dose is three times the maintenance dose.
4. The method according to claim 1 , wherein the loading dose is administered on day 1 and the maintenance dose is administered on day 2 and thereafter.
5. The method according to claim 1 , wherein the loading dose and the maintenance dose are administered at bedtime.
6. The method according to claim 1 , further comprising administering a second loading dose prior to administering the maintenance dose.
7. The method according to claim 6 , wherein the loading dose is three times the maintenance dose and the second loading dose is two times the maintenance dose.
8. The method of claim 1 , wherein the therapeutically effective maintenance dose comprises a dosage of 0.25 mg, 1 mg, or 5 mg administered once a day.
9. The method of claim 1 , wherein the therapeutically effective maintenance dose is administered once a day, once every other day, once every third day, once every fourth day, or once a week.